In the liver, β-site amyloid precursor protein cleaving enzyme 1 (BACE1), a therapeutic target of AD [277], regulates the number of IRs and insulin signaling in a glucose concentration-dependent manner [21]. The gene discussed is INS; the disease is Alzheimer disease.